Opinion|Videos|January 21, 2026
Other Key Mantle Cell Lymphoma Highlights From ASH 2025
Author(s)Luhua (Michael) Wang, MD, Nakhle Saba, MD
Michael Wang, MD, and Nakhle Saba, MD, highlight other key mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition.
Advertisement
Episodes in this series
Michael Wang, MD, and Nakhle Saba, MD, highlight additional mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition. They discuss notable trial updates, novel agents, and evolving therapeutic approaches. Wang and Saba place these findings in context of the rapidly evolving mantle cell lymphoma treatment landscape.
Advertisement
Related to this article
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5